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1. Summary 
 
Cancer is the second most frequent cause of death in developed countries. The most 
dangerous ability of cancer cells of a primary tumor is to invade adjacent or distant organs. This 
process, known as metastasis, represents the main cause of death from cancer. Among all the 
different cancer types, colorectal cancer is the second cause of death by malignant tumors in both 
Europe and US.  
The carcinogenic process in the colon starts when genetic and/or epigenetic alterations 
accumulate in normal tissue cells. Some of the mutations affect key genes involved in signal 
transduction, apoptosis, and DNA repair such as mismatch repair. In most cases, the transformation 
process, which begins in the epithelial crypts, seems to result from qualitative, quantitative, and spatial 
subversion of the Wnt signaling pathway, the physiological regulator of epithelial homeostasis. These 
early events trigger the transformation of normal cells into dysplastic cells, which proliferate and form 
benign tumors, called adenomas. Additional sequentially ordered mutations arise to end up with 
malignant lesions, named cancer. Thus, colon cancer progression can be divided in three critical 
stages; i) the normal to adenomatous cell transition, ii) the progression from adenoma to carcinoma, 
and iii) the appearance of metastasis. Clinical intervention, based on the biological knowledge of the 
different stages acquired during the last three decades, could greatly improve the management of this 
disease.  
In an attempt to discover genes responsible for the initial steps of epithelial transformation, we 
performed a comprehensive transcriptome analysis of colorectal adenomas (see Results and 
Appendix I).  
Among the most over-expressed genes in adenomas, we found KIAA1199, a gene with 
unknown function. In normal tissue, both the RNA and protein were expressed at the bottom of the 
intestinal crypts where the proliferative compartment is located. Interestingly, we saw a striking over-
expression all over the adenomatous tissue, particularly in the cytoplasm facing the crypt lumen and 
in/around the mucin vacuoles of goblet cells. The over-expression persisted during the transition from 
low-grade dysplasia with goblet-cell differentiation to high-degree dysplasia in which this differentiation 
was no longer apparent. KIAA1199 mRNA and protein were also over-expressed in advanced colon 
cancers.  
These data, taken together with other findings obtained during a collaborative work with Prof. 
Hans Clevers’ laboratory, Hubrecht Institute, Netherlands Institute for Developmental Biology, Utrecht 
(see Results and Appendix II), suggested KIAA1199 as a novel biomarker of colorectal tumors, as 
well as a new target gene of the Wnt signaling pathway.  
Briefly, we compared the list of up-regulated genes in adenomas and carcinomas (compared 
with normal mucosa), with that of genes down-regulated upon stable transfection of LS174T and DLD1 
colorectal cancer cell lines with dominant negative TCF1 or TCF4 (dnTCF1 and dnTCF4), or beta-
catenin siRNA. These dnTCFs block the formation of a transcription complex composed of beta-
catenin and the DNA-binding proteins of the T cell factor/lymphoid-enhancing factor (TCF/LEF) family. 
We assumed that genes common to both lists might be putative Wnt targets. This combined analysis 
of microarray data for tissues and cell lines placed KIAA1199 at the top of the common gene list.  
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For a better clinical management of tumors, it is essential to know the different molecular 
characteristics they acquire during transformation. Not all colorectal cancers exhibit the same features 
in terms of growth rate, aggressiveness, prognosis, etc. For example, defects in one of the DNA 
mismatch repair genes are crucial events for cancer initiation and progression in the colon and other 
organs (for details see 3.2.3.). These defects confer characteristic phenotypes to the tumors: high 
level DNA microsatellite instability, conspicuous lymphocytic infiltration, preferential location in the 
proximal colon, and better prognosis. It has been generally accepted that the better prognosis of 
mismatch repair deficient colon cancers is related to the conspicuous infiltration of CD8+ lymphocytes, 
but the molecular aspects of this histological feature have not been studied. In a microarray analysis of 
mismatch repair deficient cancers, we have identified 4-1BBL, a gene playing a key role in the anti-
tumor response, as one of the most prominently over-expressed genes in these tumors. Its over-
expression was also confirmed at the protein level with flow cytometry. We have proposed that this 
ligand presented by neoplastic cells could be a target of 4-1BB present on CD8+ cytotoxic 
lymphocytes. This finding could also be explored to identify novel approaches for the treatment of this 
subgroup of colon cancers. We also showed that MSI could conceivably be responsible for the 
decreased transcript levels of genes containing 5’-UTR or coding- region microsatellites. Alterations in 
the 5’-UTR could diminish transcription efficiency, whereas coding-region MSI would lead to 
nonsense-mediated decay of the RNA transcript. In contrast, genes whose 3’-UTRs contained long 
mononucleotide repeats generally displayed increased expression in MMR-deficient settings, and the 
3 genes of this type tested for MSI all displayed repeat shortening. The fact that in reverse-
transcription polymerase chain reaction the microsatellite-containing tracts of the 3’-UTRs of these 
genes (but not their coding regions) were amplified much more efficiently in MMR-deficient cells is 
difficult to explain, but recent evidence suggests that poly(U)-tract length can affect RNA stability and 
processing and translation efficiency (see Results and Appendix III).  
Another aspect that can affect cancer incidence is the intrinsic molecular and biological nature 
of the normal tissue of origin.  
For example, in the lower gastrointestinal tract, concretely in the ileum (the last part of the 
small intestine) and in the colon (the main part of the large bowel), cancer rates are surprisingly 
different showing an adenocarcinoma incidence in the ileum around 25 times lower than in the colon, 
despite the fact that both tissues have high proliferative rates.This striking difference motivated us to 
perform a comparative transcriptome analysis of these two normal tissues (see Results and 
Appendix IV).  
Although this work is still ongoing, preliminary results showed interesting transcriptional 
differences in i) genes related to cell differentiation and cell proliferation, ii) transcription regulators, iii) 
Wnt-signaling pathway genes, and iv) apoptosis. 
In this last group of genes, two pro-apoptotic genes members of the cell death-inducing DFFA-
like effectors family, CIDEB and CIDEC, were found significantly under-expressed in colon compared 
with ileum. In addition, transcript levels for these genes were further down-regulated in colon 
adenomas and adenocarcinomas. These findings raise the question of whether the down-regulation of 
Summary 
 7
pro-apoptotic genes in normal colon might be related to a higher predisposition to cellular 
transformation in this organ. 
In conclusion, during my PhD studies, we have 1) characterized the transcriptome of normal 
epithelia of the lower gastrointestinal tract, and of benign and malignant tumors of the colon, 2) 
identified novel molecular markers of adenomatous transformation and of advanced colon cancer with 
defective mismatch repair system, 3) identified new putative Wnt target genes in colon adenomas and 
carcinomas.  
We strongly believe the data we produced could give important hints to better understand 
colon carcinogenesis and to improve its clinical treatment. 
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2. Zusammenfassung 
 
Krebs ist die zweithäufigste Todesursache in entwickelten Ländern. Die wohl gefährlichste 
Eigenschaft von Krebszellen eines primären Tumors ist es, in umliegende oder entfernte Organe 
vorzudringen. Dieser Prozess, bekannt unter dem Begriff Metastasieren, ist der Hauptgrund für den 
tödlichen Verlauf von Krebs. Unter all den verschiedenen Typen ist der kolorektale Krebs die 
zweithäufigste Todesursache durch bösartige Tumoren, und dies sowohl in Europa als auch in den 
US. 
Durch die Ansammlung von genetischen und/oder epigenetischen Veränderungen in 
normalen Gewebezellen startet der karzinogene Prozess im Dickdarm. Einige der bekannten 
Mutationen betreffen Gene, welche Schlüsselfunktionen in Signaltransduktion, Apoptosis und DNA-
Reparatur (z.B. Fehlpaarungsreparatur (MMR)) einnehmen. Der Transformationsprozess, welcher im 
Krypten-Epithel beginnt, scheint in den meisten Fällen das Resultat qualitativer, quantitativer und 
räumlicher Zerstörung des Wnt-Signalweges zu sein. Der Wnt-Signalweg ist der physiologische 
Regulator der Epithel-Homöostase. Diese frühen Ereignisse lösen die Transformation von normalen 
Zellen in fehlgebildete, dysplastische Zellen aus. Letztere proliferieren und bilden gutartige Tumoren, 
sogenannte Adenome. Entstehen weitere sequenziell angeordnete Mutationen führt dies zu 
bösartigen Läsionen, sprich Krebs. Deshalb kann das Fortschreiten von Dickdarmkrebs in drei 
kritische Phasen unterteilt werden: i) Transition von normalen Zellen zu adenomatösen Zellen, ii) der 
Verlauf von Adenoma zu Karzinoma und iii) das Auftreten von Metastasen. Durch das fundierte 
biologische Verständnis dieser verschiedenen Phasen konnten die klinischen Behandlungsansätze für 
die Krankheit in den letzten drei Jahrzehnten stark verbessert werden.  
In einem Versuch, die für die initialen Schritte der Epithel-Transformation verantwortlichen 
Gene zu finden, führten wir eine umfassende Transkriptom-Analyse von kolorektalen Adenomen durch 
(siehe Results and Appendix I). 
Als eines der am stärksten überexprimierten Gene in Adenomen entdeckten wir KIAA1199, 
ein Gen mit unbekannter Funktion. In normalem Gewebe wird sowohl die RNA als auch das Protein 
selber zuunterst in den Darm-Krypten exprimiert, dort wo sich das proliferative Kompartement 
befindet. Interessanterweise sahen wir eine markante Überexprimierung im gesamten adenomatösen 
Gewebe, speziell in dem dem Krypten-Lumen zugewandten Zytoplasma und in/um die Muzin-
Vakuolen der Becherzellen. Die Überexprimierung bestand von der Transition von low-grade 
Dysplasie mit Becherzell-Differenzierung bis hin zur hochgradigen Dysplasie bei welcher diese 
Differenzierung nicht mehr vorhanden war. Die mRNA und das Protein von KIAA1199 waren auch in 
fortgeschrittenem Dickdarmkrebs überexprimiert. 
Diese Daten, zusammen mit den Resultaten aus der Kollaboration mit Prof. Hans Clever’s 
Labor, Hubrecht Institute, Netherlands Institute for Developmental Biology, Utrecht (siehe Results 
and Appendix II), lassen den Schluss zu, dass KIAA1199 sowohl ein neuer Biomarker für kolorektale 
Tumore, als auch ein neues Zielgen des Wnt-Signalweges ist. 
Kurz, wir verglichen die Liste der aufregulierten Gene in Adenom und Karzinom (verglichen 
mit normaler Mukosa) mit der Liste der abregulierten Gene nach stabiler Transfektion von LS174T und 
Zusammenfassung
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DLD1 kolorektalen Krebszell-Linien mit dominant-negativem TCF1 oder TCF4 (dnTCF1 and dnTCF4), 
oder beta-catenin siRNA. Die dnTCFs verhindern die Bildung von Transkriptionskomplexen bestehend 
aus beta-catenin und den DNA-Bindungsproteinen der T cell factor/lymphoid-enhancing factor 
(TCF/LEF)-Familie. Wir vermuteten, dass Gene, die auf beiden Listen erscheinen, mögliche Wnt-
Zielgene sein könnten. Diese kombinierte Microarray-Daten-Analyse für Gewebe und Zell-Linien 
rückte KIAA1199 an die Spitze der gemeinsamen Gen-Liste. 
Um Tumoren in der Klinik besser behandeln zu können ist es unabdingbar, die verschiedenen 
molekularen Eigenschaften, welche durch Transformation entstehen, genau zu kennen. Nicht jeder 
kolorektale Krebs zeigt die gleichen Verhaltensweisen in bezug auf Wachstumsgeschwindigkeit, 
Aggressivität, Prognose etc. Zum Beispiel sind Defekte in einem an der Fehlpaarungs-Reparatur 
beteiligten Gen eine massgebliche Voraussetzung für den Beginn und das Fortschreiten von Krebs im 
Dickdarm und anderen Organen (für Details siehe 3.2.3.). Diese Defekte verleihen dem Tumor einen 
charakteristischen Phänotyp: ein hohes Niveau an DNA Mikrosatelliten-Instabilität (MSI), auffällige 
lymphozytäre Infiltration, bevorzugte Lokalisation im proximalen Dickdarm und bessere Prognosen. Es 
ist generell bekannt, dass die bessere Prognose von Fehlpaarungs-Reparatur-defizientem 
Dickdarmkrebs mit der auffälligen Infiltration von CD8+-Lymphozyten zusammenhängt, wobei die 
molekularen Aspekte dieser histologischen Eigenart nie studiert wurden. In einer Microarray-Analyse 
von Fehlpaarungs-Reparatur(MMR)-defizientem Krebs identifizierten wir das Gen 4-1BBL, welches 
nicht nur eine Schlüsselrolle in der Anti-Tumor-Antwort spielt sondern auch eines der am stärksten 
überexprimierten Gene in diesen Tumoren ist. Die Überexprimierung dieses Genes wurde auch auf 
Proteinebene mittels Durchfluss-Zytometrie bestätigt. Wir könnten uns vorstellen, dass dieser Ligand 
von neoplastischen Zellen präsentiert wird und ein Ziel von 4-1BB sein könnte, welches wiederum auf 
zytotoxischen CD8+-Lymphozyten vorhanden ist. Diese Erkenntnis könnte auch dazu benutzt werden, 
neue Behandlungsansätze für diese Krebs-Untergruppe zu identifizieren. Wir konnten auch zeigen, 
dass MSI möglicherweise verantwortlich für die verminderte Transkription von Genen ist, welche 
Mikrosatelliten entweder im 5’-UTR-Abschnitt oder in den kodierenden Regionen beherbergen. 
Veränderungen im 5’-UTR-Abschnitt könnte die Transkriptions-Effizienz abschwächen, während 
Mikrosatelliten in den kodierenden Regionen non-sense mediated decay der RNA-Transkripte zur 
Folge haben könnte. Auf der anderen Seite zeigten Gene, welche 3’-UTR mit langen Mononukleotid-
Wiederholungen enthielten, generell erhöhte Exprimierung in MMR-defizienten Einstellungen. Drei auf 
MSI untersuchte Gene dieses Typs waren durch Verkürzungen in den Wiederholungen charakterisiert. 
Die Tatsache, dass in MMR-defizienten Zellen die Mikrosatelliten-enthaltenden Bereiche in den 3’-
UTR-Abschnitten dieser Gene wesentlich effizienter mittels reverse-transcription polymerase chain 
reaction (RT-PCR) amplifiziert wurden, ist schwierig zu erklären. Neueste Erkenntnisse lassen aber 
vermuten, dass die Länge von poly(U)-Abschnitten die Stabilität, die Prozessierung und die 
Translations-Effizienz von RNA beeinflussen kann (siehe Results and Appendix III). 
Die intrinsische molekulare und biologische Beschaffenheit von normalem Ursprungsgewebe 
ist ein weiterer Aspekt, welcher das Auftreten von Krebs bestimmen kann. 
Als Beispiel: Obschon sowohl im Ileum (letzter Teil des Dünndarms, auch Krummdarm 
genannt) als auch im Dickdarm (auch Grimmdarm genannt) die Gewebe hoch-proliferativ sind, ist das 
Zusammenfassung
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Auftreten von Adenokarzinomen überraschenderweise im Ileum zirka 25-mal seltener als im 
Dickdarm. Dieser markante Unterschied hat uns motiviert, eine vergleichende Transkriptom-Analyse 
von diesen beiden normalen Geweben durchzuführen (siehe Results and Appendix IV). 
Obschon wir diese Arbeit noch nicht abgeschlossen haben, geben die ersten Resultate 
interessante Hinweise: wir beobachten transkriptionelle Unterschiede in i) Genen, welche mit Zell-
Differenzierung und Zell-Proliferierung in Verbindung stehen, ii) Transkriptions-Regulatoren, iii) Genen 
des Wnt-Signalweges und iv) Apoptosie. 
In der letztgenannten Gruppe von Genen fanden wir zwei pro-apoptotische Mitglieder der cell 
death-inducing DFFA-like effectors-Familie, nämlich CIDEB und CIDEC. Verglichen mit dem Ileum 
waren beide deutlich unterexprimiert im Dickdarm. Dazu kommt, dass bei diesen Genen das Level der 
Transkripte in Dickdarm-Adenomas und Adenokarzinomen noch weiter abreguliert war. Die Frage 
stellt sich nun, ob Abregulierung von pro-apoptotischen Genen in normalem Dickdarmgewebe 
vielleicht mit einer höheren Prädisposition für zelluläre Transformation in diesem Organ verbunden ist. 
Zusammenfassend kann man sagen, dass wir während meiner Doktorarbeit 1) das 
Transkriptom von normalem Epithel des unteren gastrointestinalen Trakts und von gut- und bösartigen 
Dickdarmtumoren charakterisiert, 2) neue molekulare Marker der adenomatösen Transformation und 
des fortgeschrittenen Dickdarmkrebs mit defektivem MMR-System identifiziert und 3) ebenso neue 
mögliche Wnt-Zielgene in Dickdarm-Adenomen und –Karzinomen identifiziert haben. 
Wir glauben, dass unsere Daten wichtige Hinweise für ein besseres Verständnis der 
Dickdarm-Karzinogenese liefern und dadurch die klinischen Behandlungen verbessert werden 
können. 
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3. Introduction 
According to the World Health Organization (WHO), the top-5 causes of human mortalism in 
developed countries are i) cardiovascular diseases, ii) cancer (malignant neoplasm), iii) 
cerebrovascular diseases (stroke), iv) chronic obstructive pulmonary diseases (emphysema, chronic 
bronchitis), and v) accidents (unintentional injuries).  
On the other hand, the situation in developing countries is different because of shorter life 
span, due to the lower living standards (lack of potable water, food, and access to medicines) and 
deficient information and education. The shortest life span decreased the incidence of “developed 
diseases”, like cancer, associated with aging. In contrast, HIV-AIDS (on the top of the list) and 
parasitic diseases (such as diarrhea, malaria), pathologies under control in developed countries, are 
primary causes of death. 
 Cancer, being the second most frequent cause of death in developed countries, is a public 
health problem that costs thousands of billions every year. For this reason, its prevention, detection, 
treatment, and cure has become a topic of primary interest for thousands of research groups all over 
the world.  
 
3.1. Cancer  
 The term cancer encloses a vast group of diseases that can arise in almost any part of the 
body. The process by which cancer appears and develops is called carcinogenesis and it is 
characterized by the rapid and uncontrolled proliferation of cells and their capacity to invade adjacent 
tissues, or to be transported through the blood stream or lymphatic system to occupy distant tissues, 
in a process known as metastasis. Metastasis is the major cause of death from cancer.  
Cancer risk is thought to be related to age because the increased and uncontrolled growth of 
the cells is caused by mutations in the DNA and DNA damage, more frequent in aging DNA. Although 
many mutations arise during DNA replication, there are many mechanisms to repair them and also 
many mutations are necessary for the transformation of a normal cell into a cancer cell. Mutations in 
the DNA are a result of the interaction between genetic factors of the host and external agents of 
different origin; physical (ultraviolet and ionizing radiation), chemical (asbestos, tobacco, alcohol…), or 
biological (virus, bacteria, and parasites) carcinogens. Cancers can be sporadic, most of them, or 
inherited, which then are called syndromes. 
 
3.1.1. Classification 
The abnormal and disorganized growth in a tissue or organ, usually forming a distinct mass of 
cells, is called neoplasia or tumor. Tumors can be benign or malignant (cancer). Cancers can be 
classified according to the tissue origin of the tumor: carcinomas, lymphomas and leukemias, 
sarcomas, mesotheliomas, gliomas, germinomas, and choriocarcinomas.  
Carcinomas: these malignant tumors are derived from epithelial cells and are the most 
common type of cancers. Carcinomas invade surrounding tissues and organs, and may spread to 
Introduction 
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lymph nodes and distal sites (metastasis). In this group we included breast, prostate, lung and colon 
cancers. They can be classified by their histopathological appearance:  
Adenocarcinomas are malignant tumors originating in the epithelial cells of glandular tissues.  
Squamous cell carcinomas show squamous cell differentiation. Squamous cell carcinoma is 
usually developed in the epithelial layer of the skin and sometimes in various mucous membranes of 
the body. 
Small cell carcinomas are usually associated with the lung, though they can be associated 
with other topographies, such as in cervical cancer.  
Lymphomas and Leukemias: these are malignant tumors derived from blood and bone 
marrow cells characterized by an abnormal proliferation of blood cells, usually white blood cells 
(leukocytes).  
Sarcomas: are cancers that arise from connective tissue, or mesenchymal cells 
Mesothelioma: tumors derived from the mesothelial cells lining the peritoneum and the 
pleura.  
Gliomas: are primary central nervous system (CNS) tumors that arise from glial cells. The 
most common site of involvement of a glioma is the brain, but they can also affect the spinal cord, or 
any other part of the CNS, such as the optic nerves. 
Germinomas: are malignant tumors which most closely resemble germ line cells. These 
types of neoplasia are usually found in the testes or ovaries. Germinoma found outside these areas 
may be referred to as dysgerminomas. 
Choriocarcinomas: are malignant and aggressive cancers of the placenta. They are 
characterized by early hematogenous spread to the lungs. 
 
3.1.2. Worldwide incidence and death rates 
 In Europe and the United States of America (US), cancer incidence and death rates are very 
similar1, 2. Because of the increasing age of the population, the number of cancer cases will continue 
to increase every year, although the knowledge about these diseases and the mechanisms to prevent, 
detect, and treat them, have remarkably improved in the last decades.  
 In Europe, there were almost 3 millions new cancer cases in 20041 (Figure 1). The highest 
incidence percentages were registered for lung (13.2%), colorectal cancer (CRC; 13.0%), and breast 
(12.8%) cancers. The cancers with the highest mortality were lung (20%), CRC (11.9%), and stomach 
(8.1%). Dividing the statistics by gender, the most frequent cancers in men affected lung (19.5%), 
prostate (15.5%), and CRC (12.8%) whereas in women, breast (27.4%), CRC (13.3%), and uterus 
(9.9%) cancers were the most common malignant tumors observed. In terms of death rates, lung 
(27.9% and 9.8%, in men and women, respectively), CRC (10.7% and 13.3%, in men and women, 
respectively), prostate (15.5% in men), and breast (17.4% in women) cancers comprised top-3 for 
each gender.  
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In the US, the statistics from 20052 were similar to those of the European but with some 
noteworthy differences (Figure 2). In men, prostate, lung, and CRC were, as in Europe, the three 
cancer types with the highest number of new cases but while lung and CRC percentages were smaller 
(13.1% to 19.5% and 10.1% to 12.8%, respectively), the percentage of prostate cancer was the 
double (32.7% to 15.5%).  In women, breast and CRC cancers have similar incidence percentages to 
the European ones (31.9% to 27.4% and 11.1% to 13.3%, respectively) but lung occurrence is higher 
(12% to 6.1%). The highest mortality accounts for lung (26.6%), breast (14.7%), and CRC (9.4%), like 
in Europe, but the deaths due to lung cancer are almost three times more frequent in the female 
population of US than in the European one. 
 
 
  
Interesting information can be extracted from these data. The first striking fact refers to the 
huge increase of prostate cancer incidence and death rates in the US male population compared to 
Europe. The second remarkable observation is the enormous increase of the incidence and death 
rates of lung cancer among US female inhabitants compared to women in Europe. This may be due to 
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the smoking habits of American women since it has been shown that smoking is the principle and 
most important risk factor for lung cancer. The third important piece of information points out CRC as 
the second cause of death by malignant tumors in both Europe and the US. It affects men and women 
at the same rate (different from lung cancer, for example, that affects many more male than female 
subjects). Since more than two thirds of the new cases of CRC appear in developed countries, it is 
believed that this pathology is strongly influenced by social and geographic components. This is one of 
the reasons why research in the colorectal cancer field is conducted by many laboratories in the world.  
 
3.2. Colorectal Cancer (CRC) 
To better understand what is and how CRC arises it is important to have a notion about the 
physiology and the histology of the intestinal tract (see 3.2.1.). It is also mandatory to have a brief 
introduction to the intestinal cell renewal mechanism because its (de)regulation is closely linked to 
cancer onset.  
Around 200 cells per crypt (details in 3.2.1.1.) are generated every day in the intestine. This 
complicated and precise mechanism needs to be strictly controlled to preserve a correct equilibrium. 
This equilibrium is called homeostasis and it is maintained by, at least, three different coordinated 
processes: cell proliferation3, cell migration4, and anoikis.  
The intestinal cell proliferation is not individually driven by each cell type but controlled by the 
crypt niche, meaning that the two clearly defined proliferative and differentiated compartments are 
strictly preserved while the cells travel beside the crypt-villi axes5. While the location of four to six stem 
cells6, 7 at the crypt bottom in the large intestine seems to be clear, their position in the small intestine 
is less obvious; they have been placed immediately above the Paneth cells8, 9 or mixed with Paneth 
cells at the very bottom of the crypts10-13. The intestinal stem cells are characterized by preservation of 
an undifferentiated phenotype, permanent production of all different cell lineages, self-maintenance 
and renewal abilities, and regeneration capability after damage.  
The epithelium layer is subjected to a constant cell migration towards the villi or the surface 
epithelium. There are only two cell types that escape this effect; Paneth cells and stem cells.  
Finally, the processes called anoikis is the cell shedding at the top of the villi, in the small 
intestine, or at the surface of the epithelium, in the large intestine, by which the cells lose contact with 
the cellular matrix and undergo apoptosis. 
 
3.2.1. Biology of the gastrointestinal (GI) tract14-16  
The gastrointestinal tract, also called the digestive tract or gut, is a group of organs that by a 
procedure called digestion disrupts and processes the food to get energy and nutrients, discarding the 
remaining waste. In a normal human adult it is approximately 7.5 meters long.  
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3.2.1.1. Anatomy 
The GI tract is composed of two main parts; the upper and the lower gastrointestinal tract, 
separated, at the same time, in different segments (Figure 3). 
The upper GI tract encloses the mouth, the esophagus and the stomach.  
The mouth is the cavity lying at the upper 
end of the alimentary canal, bounded on the 
outside by the lips and inside by the oropharynx 
and containing in higher vertebrates the tongue, 
gums, and teeth. It is the body opening through 
which an animal takes in food and water.   
The human esophagus is about 25 cm 
long and 2.5 cm in diameter. It is the portion of the 
digestive tube that conducts food from the pharynx 
to the stomach. When food is swallowed it passes 
from the pharynx into the esophagus, initiating 
rhythmic contractions (peristalsis) of the 
esophageal wall, which propel the food along 
toward the stomach. The walls of the esophagus are lined with mucous glands that continue the 
lubrication of the food as it is conducted to the stomach. The cardia, or cardiac sphincter, is the 
anatomical term for the junction orifice of the stomach and the esophagus. At the cardia, the mucosa 
of the esophagus transitions into gastric mucosa. 
The stomach is a saclike dilation in the gastrointestinal tract between the esophagus and the 
intestines, forming an organ of digestion. The human stomach is a muscular, elastic, pear-shaped bag, 
lying crosswise in the abdominal cavity beneath the diaphragm. It is capable of gross alterations in 
size and shape, depending on the position of the body and the amount of food inside. The stomach is 
about 30.5 cm long and is 15.2 cm wide at its widest point. Its capacity is about 0.94 liters in the adult. 
Food enters the stomach from the esophagus, through the cardiac sphincter that normally prevents 
food from passing back to the esophagus. The other end of the stomach empties into the first section 
of the small intestine, or duodenum; the pyloric sphincter, which separates the two, remains closed 
until the food in the stomach has been modified and is in suitable condition to pass into the small 
intestine. The muscular action of the stomach and the digestive action of the gastric juice convert food 
in the stomach into a semiliquid state called chyme. The stomach is involved in the second phase of 
digestion, following mastication. Its primary function is to break down large molecules (such as from 
food) into smaller ones using hydrochloric acid so that they can be absorbed by the small intestine. 
Secondary functions include temporary storage of food, control of the rate at which food enters the 
duodenum, acid secretion and antibacterial action, fluidization of stomach contents, protein digestion 
using pepsin enzymes, and absorbing water, some ions, and some lipid soluble compounds such as 
alcohol, aspirin, and caffeine. The stomach's interior can secrete 2 to 3 liters of gastric fluid per day. 
 
The lower GI tract, also called bowel or intestine, is the muscular hoselike portion of the 
gastrointestinal tract extending from the lower end of the stomach (pylorus) to the anal opening and, in 
Introduction 
 16
humans and other mammals, consists of two segments, the small intestine and the large intestine or 
colon. The large intestine is wider in diameter than the small intestine and its direction as it leaves the 
cecum is upward (ascending colon), across the abdominal cavity (transverse colon) beneath the 
stomach, and then downward (descending colon) on the left side of the abdominal cavity, making a 
sharp turn in the left lower portion (sigmoid 
colon) to merge with the rectum. Bacteria, 
the indigestible residue of food, and mucus 
form the bulk of matter in the large 
intestine. The water content of the bulk is 
absorbed through the walls of the large 
intestine, and the solid matter is excreted 
through the rectum. The intestines host 
several kinds of bacteria that deal with 
molecules which the human body is not 
able to breakdown itself (Figure 4). 
The small intestine is the part of the gastrointestinal tract between the stomach and the large 
intestine. In humans it is about 5-6 m long and 2.5 cm wide. It joins the large intestine (colon) at the 
cecum in the right lower abdominal cavity. It is divided in three parts; duodenum, jejunum, and ileum. It 
is covered in wrinkles which are called plicae circulara. From the plicae circulara project microscopic 
finger-like pieces of tissue called villi. The purpose of these wrinkles and projections is to increase 
surface area for absorption of nutrients. Furthermore, each villus is covered in microvilli, which again 
increase the surface area manyfold. In this region, as well, there is the appendix, a blind pouch, of 
about 7.5 cm long and less than 1.3 cm wide, projecting from the cecum with no digestive function (it 
is considered to be a remnant of a portion of the digestive tract which was once more functional and is 
now in the process of evolutionary regression).  
The duodenum is the first and shortest (23–28 cm) segment of the small intestine. It begins 
with the duodenal bulb and ends at the ligament of Treitz. It curves down and then up from the pylorus 
of the stomach, where chyme (the thick semifluid mass of partly digested food and secretions, formed 
in the stomach and intestines during digestion) enters it. Ducts from the pancreas and gallbladder 
bring in bicarbonate to neutralize stomach acid, pancreatic enzymes to further digestion, and bile salts 
to break up fats. Nutrient absorption begins in the lower duodenum, which has a mucous lining. 
Exposure to stomach acid makes the upper duodenum susceptible to peptic ulcers, the duodenum's 
most common problem.  
Following the duodenum there is the jejunum, the central part of the small intestine. In adults 
it is 1-2 m long and it has a great mobility, like the ileum, thanks to being suspended by the mesentery, 
a double layer of peritoneum. The inner surface of the jejunum, its mucous membrane, is covered in 
projections called villi. It differs from the duodenum due to lack of Brunner's glands. It is also different 
from the ileum due to fewer goblet cells and generally lacks Peyer's patches. 
The ileum is the final and longest (about 2-4 m) segment of the small intestine. It extends 
from the jejunum to the ileocecal valve, where it joins the cecum. Its function is to absorb vitamin B12 
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and bile salts. The wall itself is made up of folds, with many villi on its surface. Moreover, the epithelial 
cells which line these villi possess even larger numbers of microvilli. As a result, the ileum has an 
extremely large surface area both for the adsorption of enzyme molecules and for the absorption of 
products of digestion. The cells that line the ileum contain the protease and carbohydrase enzymes 
responsible for the final stages of protein and carbohydrate digestion. These enzymes are present in 
the cytoplasm of the epithelial cells. The villi contain large numbers of capillaries which take the amino 
acids and glucose produced by digestion to the hepatic portal vein and the liver. A difference between 
the ileum and the other regions of the small intestine is its lymphoid tissues. While the length of the 
intestinal tract contains lymphoid tissue, only the ileum has abundant Peyer's patches, 
unencapsulated lymphoid nodules containing large amounts of lymphocytes and other cells of the 
immune system. 
The small intestine has different functions; it is not only an organ of digestion (for that part of 
the process not completed by the stomach) but is the chief organ of absorption; it is the site where 
most of the nutrients from ingested food are absorbed. By contraction of its muscular walls (peristalsis) 
the food mass is propelled onward and, as it is carried along, it is subject to the digestive action of the 
secretions of the intestinal lining as well as to that of bile and pancreatic juice which enter the upper 
intestine (duodenum) from ducts leading from the liver and pancreas. The digestion of proteins into 
peptides and amino acids principally occurs in the stomach but some also occurs in the small 
intestine. The small intestine is where the majority of chemical digestion takes place; peptides are 
degraded into amino acids; lipids (fats) are degraded into fatty acids and glycerol; and carbohydrates 
are degraded into simple sugars (e.g., glucose). 
There are many diseases affecting the small intestine. Here, I will just briefly mention two of 
them: Crohn’s Disease and small intestine cancer.  
Cancer of the small intestine is relatively rare compared to colorectal cancer17. It can be 
subdivided into duodenal cancer, and cancer of the jejunum and ileum. The different subtypes of small 
intestine cancer include adenocarcinomas, gastrointestinal stromal tumor, lymphoma, and carcinoid.  
Crohn's disease (CD) is a chronic, episodic disease which can affect any part of the 
gastrointestinal tract from mouth to anus. Because it is a systemic disease, it can also cause 
complications outside of the gastrointestinal tract18. The main gastrointestinal symptoms are 
abdominal pain and diarrhea, which may be bloody. Symptoms outside the gastrointestinal tract 
include skin rashes, arthritis, and ulcers in the mouth. CD is a type of inflammatory bowel disease 
(IBD). IBD occurs when the immune system contributes to damage of the gastrointestinal tract by 
causing inflammation. Crohn's disease can be difficult to distinguish from other forms of IBD such as 
ulcerative colitis. Because of the name, IBD can be confused with irritable bowel syndrome (IBS), a 
less serious condition. CD affects between 400000 and 600000 people in North America19. Prevalence 
estimates for Northern Europe have ranged from 27–48/10000020. Although the cause of Crohn's 
disease is not known, it is widely believed to be an autoimmune disease. There is a genetic 
component to susceptibility, and the disease may be triggered in a susceptible person by 
environmental factors. Unlike the other major type of IBD, ulcerative colitis, there is no known medical 
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or surgical cure for Crohn's disease. Many medical treatments are however available for Crohn's 
disease with a goal of keeping the disease in remission21.  
The large intestine is the other segment of the lower GI tract. It extends from the end of the 
ileum to the anus. It is divided into the cecum, the colon, the rectum and the anus. The large intestine 
is longer in herbivores and shorter in carnivores, and is about 1.2 to 1.8 m long in humans. Its caliber, 
greater than that of the small intestine, is largest at its commencement at the cecum, and gradually 
diminishes as far as the rectum, where there is a dilation of considerable size just above the anal 
canal.  
The first part of the large intestine is the cecum. It is a pouch of about 7.5 to 8.5 cm in 
diameter connected to the ascending colon and the ileum. It is separated from the ileum by the 
ileocecal valve (ICV) or Bauhin's valve, and is considered to be the beginning of the large intestine. 
Nearby the cecum, there is a blind-ended tube called the appendix. It develops 
embryologically from the cecum. It averages 10 cm in length, but can range from 2-20 cm. The 
diameter of the appendix is usually less than 7-8 mm. While the base of the appendix is at a fairly 
constant location, the location of the tip of the appendix can vary from being retrocaecal to being in the 
pelvis to being extraperitoneal. In most people, the appendix is located at the lower right quadrant of 
the abdomen. Currently, the function of the appendix, if any, remains controversial in the field of 
human physiology. One explanation has been that the appendix is a remnant of an earlier function, 
with no current purpose. 
The colon is the part of the intestine located between the cecum and the rectum. It consists of 
different segments; the ascending colon, the transverse colon, the descending colon and the sigmoid 
colon, that joins the rectum. The colon from cecum to the mid transverse colon is also known as the 
right colon. The remainder is known as the left colon. 
The first part of the colon is known as the ascending colon. The ascending colon expands 
from the cecum to the hepatic flexure (the turn of the colon by the liver). 
Following the hepatic flexure comes the transverse colon extending till the splenic flexure (the 
turn of the colon by the spleen). The transverse colon hangs off the stomach, attached to it by a wide 
band of tissue called the greater omentum. On the posterior side, the transverse colon is connected to 
the posterior abdominal wall by a mesentery known as the transverse mesocolon. The transverse 
colon is encased in peritoneum, and is therefore mobile (unlike the parts of the colon immediately 
before and after it).  
The descending colon is the part of the colon from the splenic flexure to the beginning of the 
sigmoid colon. It is retroperitoneal in two-thirds of humans. In the other third, it has a (usually short) 
mesentery. 
The sigmoid colon is the last part of the large intestine before the rectum. Its diameter is 
approximately 2.5 cm, being the narrowest portion of the colon. The walls of the sigmoid colon are 
muscular, and contract to increase the pressure inside the colon, causing the stool to move into the 
rectum. 
Next to the sigmoid colon appears the rectum, the final straight portion of the intestine, of 
about 12 to 15 cm in length, which ends in the anus. The anus is the external opening of the rectum 
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and is approximately 4 cm long. Closure is controlled by sphincter muscles. Feces are expelled from 
the body through the anus during the act of defecation, which is its primary function. 
The colon has different functions; to lubricate waste products, to absorb remaining fluids 
(added to the food during digestion), salts and vitamins, and to store waste products until excretion. It 
has no digestive function (no digestive enzymes are secreted). By the time the chyme has reached the 
colon, almost all nutrients and 90% of the water have been absorbed by the body in the small 
intestine. At this point some electrolytes like sodium, magnesium, and chloride are left as well as 
indigestible carbohydrates known as dietary fiber. As the chyme moves through the large intestine, 
most of the remaining water is removed, while the chyme is mixed with mucus and bacteria known as 
gut flora, and becomes feces.  
 
The bacteria break down some of the fiber for their own nourishment and create acetate, 
propionate, and butyrate as waste products, which in turn are used by the cell lining of the colon for 
nourishment. A part of these and other metabolic functions, the gut flora also plays important 
protective and structural roles22 (Figure 5).   
The colon is affected by several diseases such as Crohn’s disease (mentioned above) and 
cancer (see 3.2.), among many others. 
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3.2.1.2. Histology 
The GI tract has a uniform general histology with some differences which reflect the 
specialization in functional anatomy. The GI tract can be divided into 4 concentric layers surrounding 
the inner cavity, the lumen: mucosa, submucosa, muscularis propria (or m. externa), and serosa 
(Figure 6). 
 
 
 
 
 
 
 
 
 
 
 
 
The mucosa is the innermost layer of the GI tract, surrounding the lumen, or space within the 
tube. This layer comes in direct contact with the food (or bolus), and is responsible for absorption and 
secretion, important processes in digestion. The mucosa are highly specialized in each organ of the GI 
tract, facing a low pH in the stomach, absorbing a multitude of different substances in the small 
intestine, and also absorbing specific quantities of water in the large intestine. Reflecting the varying 
needs of these organs, the structure of the mucosa can consist of invaginations of secretory glands, 
like the gastric pits, or it can be folded in order to increase surface area, for instance villi and microvilli 
(only present in the small intestine)  
(Figure 7).  
The intestinal villi, fingerlike 
projections that protrude into the intestinal 
lumen, are approx. 0.5-1.5 mm long and 
cover the mucosal surface. The microvilli, 
sub-light microscopic tubular projections, 
are extensions of the apical cell membrane 
and compose the brush border. This 
complex membranous network contains 
the enzymes, receptors, and carriers 
required for terminal digestion and 
absorption. It can be divided into 
epithelium, lamina propria (connective 
tissue core), and muscularis mucosae 
(layers of smooth muscle). 
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The intestines contain a complex, rapidly proliferating, and perpetually differentiating 
epithelium. The epithelium constitutes the major barrier between the intestinal lumen and the lamina 
propria and regulates fluxes between these two compartments. Epithelial cell migration and 
differentiation occurs continuously, and the process of cellular renewal takes approximately three to 
five days. Cellular differentiation starts during migration to the upper part of the crypt (Lieberkühn 
crypts) and to the villi base. Microvilli become more prominent, and the cell’s capacity to absorb lipids, 
sugars, and amino acids increases. Shedding cells are removed from the top of the villi (in the small 
intestine) and the crypts (in the large intestine) by a process known as anoikis, in which altered cellular 
adhesion results in apoptosis (Figure 8).  
 
The epithelial cells are replaced by replication of the descendants of epithelial stem cells, 
believed to reside in the lower crypt region, approximately four to five cell positions above the crypt 
base (small intestine) or at the bottom of the crypt (large intestine). The anchored stem cells are the 
source of the four principal differentiated epithelial cell types in the adult intestinal epithelium23, 24; the 
enterocytes (absorptive cells), the goblet cells, the endocrine cells, and the Paneth cells (Figure 9). 
The cells that are fated to become the enterocytes or absorptive cells, the most abundant of 
the epithelial cells, begin to express a variety of specific genes which enable these cells to digest and 
absorb many different nutrients.  
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The role of goblet cells is to secrete mucus, a viscous fluid composed primarily of highly 
glycosylated proteins called mucins suspended in a solution of electrolytes. Mucus serves many 
functions, including protection against shear stress and chemical damage. They are present 
throughout the entire GI tract but they are more numerous in the ileum than in the jejunum. These cells 
exhibit a brandy-goblet shape and are characterized by apically located granules filled with mucins.  
The intestine contains remarkably complex types of endocrine cells. Although they all arise 
from a common stem cell, there may be a branch point at which proliferating progenitor cells 
differentiate into the various endocrine cell lineages. The secretion of these cells may have a multitude 
of effects on the intestines, like motility and intestinal cellular secretion. They exhibit an appreciable 
basal surface, and their widths narrow superiorly so that only narrow bands of apical cytoplasm reach 
the lumen. Their secretory granules are located predominantly in the basal cytoplasm below the 
nucleus, ready to be secreted by exocytosis through the basal membrane into the lamina propria.  
 
Paneth cells are pyramid-shaped cells that reside in the crypt base and contain large 
eosinophilic secretory granules located in the apical cytoplasm. They are present in the small intestine 
but not in the colon. Paneth cells provide host defense against microbes in the small intestine. They 
are functionally similar to neutrophils. When exposed to bacteria or bacterial antigens, Paneth cells 
secrete a number of antimicrobial molecules into the lumen of the crypt, thereby contributing to 
maintenance of the gastrointestinal barrier. As said before, small intestinal crypts house stem cells that 
serve to constantly replenish epithelial cells that die and are lost from the villi. Protection of these stem 
cells is essential for long-term maintenance of the intestinal epithelium, and the location of Paneth 
cells adjacent to stem cells suggests that they play a critical role in defending epithelial cell renewal. 
The principal defense molecules secreted by Paneth cells are alpha-defensins, also known as 
cryptdin. These peptides have hydrophobic and positively-charged domains that can interact with 
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phospholipids in cell membranes. This structure allows defensins to insert into membranes, where 
they interact with one another to form pores that disrupt membrane function, leading to cell lysis. Due 
to the higher concentration of negatively-charged phospholipids in bacterial than vertebrate cell 
membranes, defensins preferentially bind to and disrupt bacterial cells, sparing the cells they are 
functioning to protect. Paneth cells are stimulated to secrete defensins when exposed to bacteria (both 
Gram positive and negative types) or such bacterial products as lipopolysaccharide, muramyl 
dipeptide and lipid A. In addition to defensins, Paneth cells secrete lysozyme and phospholipase A2, 
both of which have clear antimicrobial activity. This battery of secretory molecules gives Paneth cells a 
potent arsenal against a broad spectrum of agents, including bacteria, fungi and even some 
enveloped viruses. 
The lamina propria extends from the simple columnar epithelium to the muscularis mucosae 
and contains many cells involved in immunologic functions. It forms the connective tissue core of the 
villus and fills the spaces between glands. Primarily a reticular tissue framework with numerous 
lymphocytes, eosinophils, and plasma cells. It has abundant plasma cells manufacture most of the 
antibody proteins.  
The muscularis mucosae are several thin layers of smooth muscle fibers located outside the 
lamina propria and adjacent to the submucosa. They are oriented in different ways which keeps the 
mucosal surface and underlying glands in a constant state of gentle agitation to expel contents of 
glandular crypts and enhance contact between epithelium and the contents of the lumen. It aids in the 
action of continued peristalsis along the gut.  
The submucosa is a loose connective tissue layer containing numerous arteries as well as 
venous and lymphatic plexuses that support the mucosa, and muscularis mucosae. It also joins the 
mucosa to the bulk of underlying smooth muscle. Typical connective tissue cells are also present, but 
vascular structures predominate, consistent with the role of this portion of the gut as a conduit for 
absorptive and digested products. Tiny parasympathetic ganglia are scattered around forming the 
submucosal plexus, or "Meissner's plexus", where preganglionic parasympathetic neurons synapse 
with postganglionic nerve fibers that supply the muscularis mucosae. 
The muscularis propria (m. externa) consists of a circular inner muscular layer and a 
longitudinal outer muscular layer condensed into three bands, the teniae coli. The circular muscle 
layer prevents the food from going backwards and the longitudinal layer shortens the tract. The 
coordinated contractions of these layers are called peristalsis and propel the bolus, or balled-up food, 
through the GI tract. Between the two muscle layers are the myenteric muscle or Auerbach’s plexa. 
The serosa is a mesothelial cell layer overlying loose connective tissue coated in mucus to 
prevent friction damage from the intestine rubbing against other tissues. The mesothelium consists of 
a single layer of vascular flat nucleated cells (simple squamous epithelium) which produce the 
lubricating serous fluid. This fluid has a consistency similar to thin mucous. These cells are bound 
tightly to the underlying connective tissue. The connective tissue layer provides the blood vessels and 
nerves for the overlying secretory cells, and also serves as the binding layer which allows the whole 
serous membrane to adhere to organs and other structures. 
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The four concentric layers mentioned above, surround the interior part of the GI tract, called 
lumen. The lumen is the cavity where digested material passes through and from where nutrients are 
absorbed. The luminal content of the gut is mostly water and therefore chemically represents an 
aqueous phase. Depending on the location of the gut, the aqueous phase contains acid (i.e., 
stomach), digestive enzymes (i.e., mouth, esophagus, stomach, and small intestine), or bacteria (i.e., 
predominatly large intestine). 
 
3.2.2. Signaling Pathways involved in CRC  
 Proliferation, cell fate specification, differentiation, migration, and cell death in the intestinal 
tract are precise and complex processes that are regulated through highly synchronized and 
interconnected developmental programs25, 26.  
The evolutionary conserved Wnt27, 28, Notch29, 30, TGF-Beta31, 32, BMP33, 34, Hedgehog35, 36, and 
RAS/RAF37, 38 signaling pathways have been shown to be key players in the maintenance and control 
of homeostasis and anoikis of the small and large intestines.  
Many sporadic tumors as well as hereditary syndromes arise and progress due to 
deregulation (i.e., activation or inactivation) of these signaling cascades. This fact points out how 
essential and crucial is the correct and controlled functionality of these pathways is in distinguishing 
the thin line that separates the accurate proliferation/differentiation equilibrium from the apparition of 
tumor pathologies in these tissues.  
 
Wnt signaling pathway 
The Wnt signaling pathway is highly conserved among all metazoa. Our knowledge about this 
pathway comes from genetic approaches done in nematode, Drosophila, Xenopus, zebrafish, and 
mouse39, combined with biochemical approaches (Figure 10). 
 
 
The Wnt signaling pathway is the physiological regulator of epithelium homeostasis24, 40, 41. 
The canonical Wnt signaling pathway is activated when the secreted Wnt glycoproteins bind to the 
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complex formed by the frizzled (Fz; seven transmembrane receptors) and LRP5/6 (single 
transmembrane co-receptors members of the low-density lipoprotein receptor related family) 
receptors. 
There are secreted frizzled-related (SFRPs) proteins that bind to the Wnt ligands and block 
the interaction with Fz proteins. LRP5/6 can also be blocked by other factors (for example, Dkk-1). 
When the Wnt ligands can not interact with the Fz and LRP5/6 receptors, APC, together with AXIN2, 
CK1, GSK3-beta, and others, forms a complex in the cytoplasm. CK1 and GSK3-beta sequentially 
phosphorilate beta-catenin, the central player of this cascade, which is targeted for degradation by the 
ubiquitin-proteosome pathway.  
When the signaling cascade is activated by the Wnt ligands the destruction complex is not 
active anymore leading to beta-catenin accumulation. Then, beta-catenin translocates into the 
nucleus, where it interacts with the DNA-binding proteins of the T cell factor/lymphoid-enhancing factor 
(TCF/LEF) family to form a transcription complex involved in transcriptional activation of many target 
genes.  
Several sources of evidence suggest that Wnt signaling to be activated in intestinal 
proliferative cells42-44; i) nuclear accumulation of beta-catenin, ii) presence of CRC after mutational 
activation of the signaling cascade, iii) loss of proliferation after mutation of the TCF/LEF family 
member TCF445, iv) change of CRC cells phenotype (from a crypt-like phenotype to a differentiated 
villi epithelial phenotype) after inhibition of beta-catenin/TCF4 activity46, 47, and v) reduction of epithelial 
proliferation and loss of crypts after targeted expression of Wnt inhibitors48.  
The link between Wnt signaling deregulation and CRC has been largely investigated. It has 
been shown that mutations in APC gene resemble in upregulation of beta-catenin nuclear and 
cytoplasmic levels49, 50. Mutations in AXIN2 or beta-catenin itself also lead to accumulation of beta-
catenin in the nucleus and activation of the bet-catenin/TCF4 transcription complex41, 51. Many studies 
have been done to find out Wnt target genes but the final list is still far from completion47, 52.  
Many animal models have been created to try to better understand this pathway and its 
implication in intestinal cancer, the Min mouse model (Min: multiple intestinal neoplasia; is a mutant 
allele of murine APC encoding a nonsense mutation in codon 850) being the most commonly used. 
Another mutation, the APC∆716, gives a truncated protein of 716 amino acids. Heterozygous mice for 
the Min or the APC∆716 mutations get dozens of 
adenomas53-55.   
 
Notch signaling pathway 
Intestinal homeostasis is under the control of 
various developmental signaling pathways one of 
which is the Notch signaling pathway. Many cell fate 
decisions and differentiation processes are regulated 
by Notch genes.  
Notch genes are single transmembrane 
receptors conserved through evolution. There are four 
different Notch receptors (NOTCH1/2/3/4) and five 
Introduction 
 26
ligands (DLL1/3/4; JAG1/2)56. When receptors are activated by transmembrane ligands of neighboring 
cells 29, a cascade of proteolytic cleavages of the receptor close to and within the transmembrane 
domain starts. This leads to the release and translocation of the Notch intracellular domain (NICD) into 
the nucleus where the transcription factor CSL (CBF1/RBPjk) engages and activates transcription56, 57 
(Figure 11).  
Lack of Notch signaling makes CSL to function as a transcriptional repressor.  In clusters of 
precursor cells, Notch controls cell fate choices between adjacent cells. The signal cascade is 
triggered when a cell reaches higher levels of ligands than the surrounding neighboring cells. There 
are many known Notch target genes but some of the best characterized ones are members of the 
hair/enhancer of split (HES) family of transcriptional repressors, which are nuclear basic helix-loop-
helix (bHLH) proteins. In turn, these HES proteins regulate downstream genes58, 59.  
Much work has been done with animal models to understand the Notch signaling and its 
implications in intestinal cell fate60-68.  
 
TGF-Beta signaling pathway 
Many important biological processes, such as angiogenesis, cell differentiation and 
proliferation, wound healing, and embryonic development, are controlled and regulated by the TGF-
beta signaling pathway32, 69, 70.  
The family of TGF-beta cytokines is vast and includes the TGF-beta family members, bone 
morphogenic proteins (BMPs), and activins. The two surface serine-threonine kinase receptors (type I 
and type II) are brought together by the ligands and this leads to the phosphorylation of the first 
receptor by the second. There are three different classes of SMAD proteins, which are the intracellular 
messengers of this pathway: receptor-
regulated SMADs (R-SMADs: 
SMAD1/2/3/5/8), common SMAD (co-
SMAD: SMAD4), and inhibitory SMADs (I-
SMADS: SMAD6/7). The association 
between activated type I receptors and 
SMAD4 cause R-SMADs phosphorylation 
and translocation into the nucleus (Figure 
12). There, transcription of target genes is 
regulated by the interaction between the 
SMAD complex with coactivators or 
corepressors of transcription. SMAD2/3 are 
the primary mediators in TGF-beta 
signaling whereas SMAD1/5/8 mediate 
BMP signaling.  
 TGF-beta signaling has been shown to be altered in CRC, concretely at the 
adenoma/carcinoma transition71. The inactivation of the TGF-beta receptor type II (TGFBR2) is the 
most frequent mutation and affects either microsatellite stable (MMS) and unstable (MMI) tumors72, 
although SMAD2 and SMAD4 are also mutated in CRC73, 74. A number of animal models have been 
Introduction 
 27
created to investigate the function of TGF-beta signaling in development and disease. Inactivating 
mutations for TGFB1/2/3, TGFBR2, SMAD2, SMAD3, and SMAD4 have been reported75, 76. 
Interestingly, in a SMAD4 deficient homozygosity, benign adenomas in APC∆716 mice progressed to 
carcinomas very quickly77. Based on the results obtained in animal models, the absence of TGF-beta 
signaling more than to initiate tumorigenesis, accelerates the development of already existant early 
tumors.  
 
BMP signaling pathway 
As well as the above mentioned TGF-beta signaling pathway, BMP modifies target gene 
transcription by receptor–mediated intracellular signaling34 (Figure 13).   
There are two types of BMP receptors; type I (BMPR1A and BMPR1B) and type II (BMPR2). 
In the canonical BMP pathway, BMP receptors type I activate SMAD1/5/8 by phosphorylation78. A 
dimer of phosphorylated R-SMADs then forms a complex with SMAD4. This heterodimic complex 
translocates into the nucleus and binds to 
transcription factors regulating the 
expression of target genes31, 69. A non-
canonical BMP pathway is driven by 
TGFh1 activated tyrosine kinase 1 (TAK1, 
a MAPKKK) and through mitogen 
activated protein kinase (MAPK)31, 79. In 
addition, X-linked inhibitor of apoptosis 
(XIAP) links the BMP receptor signal to 
TAK1, and TAK1 binding proteins 
(TAB1/2/3) are also required for BMP-
mediated TAK1 activation80, 81. TAK1 can 
also trigger Jun N-terminal kinase (JNK) 
and NF-kB82.  
In the canonical BMP pathway, 
SMAD function can be inhibited through blocking its translocation to the nucleus by Erk, in response to 
GF/CK signaling through Ras/Raf/Mek83. Germline mutations affecting SMAD4 or BMPR1A are 
associated to 50% of Juvenile Polyposis Syndrome (JPS)84-86.  
In this case animal models also help to understand the mechanism of this pathway and its role 
in JPS87.  
 
Hedgehog signaling pathway 
 Hedgehog ligands control cell fate specification during development.  
The 12-transmembrane protein called Patched (PTCH) is the receptor for secreted Hedgehog 
proteins (HH). In the absence of ligand, PTCH inhibits Smoothened (SMO), a 7-transmembrane 
protein, blocking the signaling cascade88. When HH binds to PTCH89 releases SMO inhibition, leading 
to activation of the GLI family of Zn-finger transcription factors (GLI1/2/3)90 (Figure 14). Activated GLI 
accumulates in the nucleus91 and controls the transcription of Hedgehog target genes92-94.  
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Mutations in the Hedgehog pathway are associated with multiple malformations along the GI 
tract95-97. The development of sporadic tumors of the skin, cerebellum, and skeletal muscle are related 
to activating mutations of the Hedgehog signaling pathway98, 99.  
 
 
The autocrine/paracrine activation of the Hedgehog pathway in the esophagus, stomach, 
biliary tract, or pancreas (all of them members of the upper GI tract) seems to be critical for tumor 
growth100, 101. 
 
RAS/RAF signaling pathway 
 The activation of the RAS/RAF/MAPK cascade supports cell proliferation and cell 
differentiation. RAS genes are GDP/GTP-regulated binary switches.  
The formation of the active GTP-bound form of RAS and its conversion to the inactive GDP-
bound state is mediated by guanine exchange factors (GEFs) and GTPase activating proteins (GAPs), 
respectively. Active GTP-bound RAS interacts with RAF (RAF1, A-RAF, or B-RAF) to form a high-
affinity complex. As a result of this interaction, RAF gets activated (Figure 15). Then a number of 
consecutive phosphorylation events take place; RAF phosphorylates MEKs (MEK1/2), which 
sequentially activates MAPKs (p42 and p44, also called extracellular regulated kinases; ERKs) by 
phosphorylation. Once phosphorylated, MAPKs translocate into the nucleus to phosphorylate a 
number of transcription factors, triggering gene expression.  
Many mutations in K-RAS and B-RAF have been associated with CRC. Around 50% of CRC 
carry an activating mutation in K-RAS102, 103. Complementation between K-RAS and B-RAF mutations 
has been described (20% of the CRC with no K-RAS mutation have B-RAF activated104, 105) and 
suggests a key role for the RAS/RAF/MAPK cascade in colorectal tumorigenesis. Interestingly, K-RAS 
mutations are more frequent in MMR-proficient tumors, whereas B-RAF mutations occur mostly in 
MMR-deficient lesions105.  
Mutations in K-RAS and B-RAF seem to be related more to cancer progression than to cancer 
initialization because they are not present in small adenomas102, 105. The function of the 
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RAS/RAF/MAPK pathway in cell renewal of the intestinal epithelium seems to be related to 
transduction of signals from the membrane to the nucleus.  
Work with animal models has not elucidated a key role for K-RAS in the initial stages of 
cancer in the intestine106-110.    
  
 
 
 
 
 
 
 
 
 
 
 
 
After this overview of the pathways that control and regulate physiologic homeostasis of the 
intestines, there are evidences that show that cancer cells have developed abilities to mutate key 
genes on these pathways to assure cancer progression. Furthermore, crosstalk mechanisms between 
them facilitate their activation through different ways, making more difficult the finding of drugs that 
could effectively block their signaling cascades to prevent cancer formation.  
 
3.2.3. DNA repair mechanisms, Mismatch Repair (MMR), and MMR defects and 
Cancer 
 The processes by which damage present in DNA molecules is detected and eliminated are 
known as DNA repair mechanisms. Every day, a cell must deal with a continuous onslaught of DNA 
lesions. This damage can come from environmental or endogenous sources. Both DNA damage 
sources result in between 1x103 and 1x106 individual molecular lesions per cell per day111.  
The vast majority of DNA damage implies a chemical modification of the bases, the primary 
structure of the double helix. A failure in repairing these kinds of lesions can trigger a harmful mutation 
rate, genomic instability, or cell death. Damage in DNA repair genes or in genes responsible of cell 
cycle regulation can lead to aggressive and invasive diseases (e.g., cancer). DNA damage during 
replication before cell division can provoke base misincorporation and therefore unrecoverable 
inheritance of mutations by the daughter cells (unless gene conversion, a rare case of back mutation, 
occurs).  
DNA repair rate depends on many factors, including cell type, age of the cell, and extracellular 
environment. Those cells carrying large amounts of DNA damage, or those in which the DNA repair 
system is not able to repair the incoming DNA damage, can follow three different processes: i) 
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senescence (or irreversible state of dormancy), ii) apoptosis (or programmed cell death), or iii) cancer 
(i.e., deregulated cell division and proliferation).  
As said, there are two different sources of DNA damage; endogenous DNA damage (i.e., 
damage generated by the byproducts of cellular metabolism: oxidation of bases and generation of 
strand interruptions by reactive oxygen species, alkylation of bases by endogenous alkylating agents, 
hydrolysis of bases such as deamination, depurination and depyrimidation, and DNA single- and 
double-strand breaks resulting from collapsed DNA replication forks or from oxidative destruction of 
deoxyribose residues112, 113), and exogenous DNA damage (such as chemical agents, UV radiation, 
and ionizing radiation). 
Depending on the type of damage done to the DNA's double helical structure, a variety of 
repair strategies have evolved to restore lost information114. If possible, cells use the unmodified 
complementary strand of the DNA or the sister chromatid as a template to losslessly recover the 
original information. Without access to a template, cells use an error-prone recovery mechanism 
known as translesion synthesis as a last resort.  
Some types of DNA damage are so common that they have their own cellular subsystem 
dedicated to counteracting them. These mechanisms do not require a template, since the types of 
damage they counteract can only occur in one of the four bases. Such direct reversal mechanisms are 
specific to the type of damage incurred.  
The damage can affect only one or both strands of the double helix. When damage consists 
on a break in both strands there are two mechanisms to repair it; non-homologous end-joining (NHEJ), 
and homologous recombination (HR) repair114, 115. When only one of the two strands is carries a 
defect, the other strand is used as a template for repairing. The mechanisms that do this kind of repair 
are base excision repair (BER), nucleotide excision repair (NER), and mismatch repair (MMR)114, 115. 
Because our institute is mainly focused on the study of the MMR system, I will explain in more detail 
how this mechanism works in prokaryotic and eukaryotic organisms. 
 
3.2.3.1. E.coli and eukaryotic MMR mechanisms 
 The major function of the postreplicative MMR system is to eliminate biosynthetic errors 
(base-base mispairs and short insertion/deletion loops, IDLs) from newly synthesized DNA. If not 
repaired, these errors will lead to base-substitutions and frameshift mutations.  
The term “postreplicative” implicates MMR in the correction of errors coming from DNA 
replication. This is due to the fact that the fidelity of polymerases implicated in DNA replication is high 
(incorrect nucleotide incorporation rate around 1x10-4-1x10-6 before intrinsic exonucleolytic 
proofreading activity and 1x10-7-1x10-8 after it116) but not enough to produce a copy of the entire 
genomic DNA without errors. MMR ensures error free duplication of the human genome by reducing 
the error rate to 1x10-9-1x10-10.  
Even though great advances in the biochemical and structural aspects of MMR have been 
achieved in the last years, the precise biological functions of the key players of the human MMR 
system have not yet been elucidated.  
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MMR proteins are divided in two categories; MutS homologues (MSH: hMSH2, hMSH3, and 
hMSH6), and MutL homologues (MLH: hMLH1 and hPMS2, where PMS stands for Post Meiotic 
Segregation). Other MLH/PMS homologues are also known (hMSH4, hMSH5, hPMS1, and hMLH3) 
but their roles are largely uncharacterized. MutS and MutL homologues need to form complexes to be 
functional (Table 1). MMR proteins, DNA replication factors (replication protein A (RPA), proliferating 
cell nuclear antigen (PCNA), replication factor C (RFC), DNA polymerase delta: Polδ), and 
exonucleolytic enzymes (exonuclease-1: EXO1) functionally interact in the human MMR machinery.  
 
 
 
 
 
 
 
 
 
 
 
The MMR is a highly conserved system from bacteria to human. Such a level of evolutionary 
conservation is due to its pivotal role in the maintenance of genomic stability. For this reason, much of 
our understanding of mammalian MMR came from studies done on E.coli and S.cerevisiae (revised 
in117-119).  
 
MMR in E.coli 
 There are two most important conditions the MMR system has to fulfill; efficient recognition of 
base-base mismatches and IDLs, and application of the repair machinery to the newly synthesized 
DNA strand, where the error has been incorporated. How these two criteria are accomplished has 
been reveled in in vitro studies using the mutS, mutL, mutH, and uvrD E.coli mutated strains120.  
When a mismatch occurs, a MutS homodimer, via ATP hydrolysis, recruits a homodimer of 
MutL to activate MutH, which then binds to a hemi-methylated GATC site (it is normally methylated on 
adenine, but transiently unmethylated because deoxyadenine methylase lags behind the replication 
fork by approximately 2 minutes) (Figure 16A).  
Once the unmethylated strand has been cleaved by the Muts/MutL-depending activated form 
of MutH, the unwinding of the ends of the error-containing strand from the template by UvrD helicase 
allows one of the 5’-3’ (RecJ or ExoVII) or 3’-5’ (ExoI, ExoVII or ExoX) exonucleases, depending on 
where the nearest hemi-methylated GATC site lies from the mismatch, to degrade the unwound DNA.  
After the mismatch has been removed, the resynthesis is mediated by DNA polymerase III 
and DNA ligase.  
 
Eukaryotic MMR mechanism 
 Even though the MMR system is conserved, the mechanism in eukaryotes is more complex 
than in E.coli. Five human MutS homologues (hMSH2, hMSH3, hMSH4, hMSH5, and hMSH6) have 
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been identified although only hMSH2, hMSH3, and hMSH6 take part in MMR (hMSH4, and hMSH5 
are exclusively involved in meiotic recombination).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Likewise, four MutL homologues are known in human cells (hMLH1, hMLH3, hPMS1, and 
hPMS2). Both types of homologues participate in the MMR in the form of heterodimers118. The 
different complexes and their known functions are described in Table 1.  
A particularly interesting characteristic of hMutL and hMutS complexes is that hMLH1 and 
hMSH2 are stable by themselves, whereas hPMS1, hPMS2, and hMSH6 need the presence of the 
corresponding interacting partner to be stable (in absence of hMLH1: hPMS1, hPMS2; and in the 
absence of hMSH2: hMSH6, degrade).  hMutLα, formed by hMLH1 and hPMS2, has the most 
important role in MMR (reviewed in121) and has been the most studied heterodimer. The role of 
hMutLγ in MMR has also recently been investigated122-124.  
As mentioned above, an important criterion that the MMR system has to satisfy is to direct the 
repair machinery to the mismatch-carrying newly synthesized strand. Interestingly, and different than 
in E.coli where MutH provides strand specificity by recognizing hemi-methylated GATC sequences, no 
MutH functional homologue has been found in other organisms. This fact may imply that the 
processing of mismatches that occur during replication could be triggered by strand breaks such as 
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the 5’ or 3’ termini of Okazaki fragments in the lagging strand, or the 3’ terminus of the leading strand 
(Figure 16B).  
The statement that something similar happens with mismatches arising during recombination, 
where the repair could be directed to the invading strand by its 3’ terminus (Figure 16C) is supported 
by in vivo125, 126 and in vitro120 experimental work with MutH deficient E.coli and by human in vitro MMR 
assays127-129.  
Based on the biochemical knowledge acquired so far, three different mammalian MMR models 
have been proposed: i) the molecular-switch model130, favors the stochastic bidirectional diffusion of 
multiple MutSα and MutLα sliding clamps from the mismatch. The repair process would start when a 
strand break tagged with other MMR features is encountered by clamps, ii) the active-translocation 
model131, 132, which hypothesizes that MutSα, probably with MutLα, after being released from the 
mismatch, translocates, in a controlled ATP hydrolysis-dependent manner, along the DNA, iii) the DNA 
bending/verification model, claims that MSH proteins remain in the proximity of the mismatch and, 
rather than protein movement along the DNA, is communication between the mismatch and the strand 
discrimination signal which involves DNA bending, although experimental evidences showed no 
satisfactory conclusions about that model133, 134. Since the first two models appear to be the most 
reliable ones, and because they only differ in the way MutSα is translated from the mismatch, they 
have been represented as one in Figure 17 (see Figure 17 legend for details).  
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3.2.3.2. MMR defects and cancer 
There are two different classes of mutations derived from the inactivation of the MMR system 
and the consequent decrease in the repair rates of the total number of errors after DNA replication: 
simple nucleotide misincorporation, and strand misalignments.  
Nucleotide misincorporations take place when DNA polymerase incorporates an erroneous 
base creating a mismatch (for example, incorporation of thymine opposite to guanine giving as a result 
a G/T mismatch) which escapes 3’-5’ exonuclease proofreading activity. When the MMR system is not 
mutated, it recognizes the mismatch and repairs it. In cells with a deficient MMR system, the mismatch 
is not recognized resulting in a G:C to T:A transversion mutation incorporated in half of the progeny 
DNA.  
Strand misalignments are due to slippage of the DNA polymerase complex during replication. 
This phenomenon is predominantly frequent in microsatellite sequences (i.e., short repetitive 
sequences) and generates “insertion/deletion” loops which are recognized and repaired by MMR. If 
not repaired, such misalignments lead to frameshift mutations. Based on experimental work with 
MMR-deficient cells, the most recurrent mutation is the loss of one unit in mononucleotide and 
dinucleotide repeats. Such an event is known as microsatellite instability (MSI)135, 136, and represents a 
hallmark of MMR-deficient tumors.  
To give uniformity to MSI analysis, a panel of five microsatellite markers, two mononucleotide 
repeats (BAT25 and BAT26) and three dinucleotides repeats (D2S123, D5S346, and D17S250), 
known as Bethesda markers, are most commonly used137. According to these markers, the degree of 
microsatellite instability of a tumor can be high (MSI-H), when two or more markers show instability, or 
low (MSI-L), when microsatellite is detected in fewer markers. Cells carrying defects in MMR genes 
have increased the risk of malignant transformation.  
Several anticarcinogenic functions of MMR genes are compromised in MMR-deficient cells: 
First, decreased genome stability, manifested as MSI all over the genome138, 139. Second, loss of 
heterology-dependent suppression of recombination, a fact that implies gene conversion and 
exposure of tumor suppressor genes to loss heterozygosity140, or chromosomal translocations141. 
Third, increased mutation rates in critical “target genes” (i.e., those with short microsatellite sequences 
in their codong sequences) involved in growth suppression142, apoptosis143, signal transduction144, 145, 
etc., resulting in growth advantage for the cells. MMR defects have been related to both hereditary and 
sporadic colon cancers (discussed in 3.2.4. and 3.2.5.), as well as to sporadic cancers in other organs 
called “sporadic tumors of the HNPCC spectrum” and “sporadic tumors not belonging to the HNPCC 
spectrum”, respectively146.  
 
3.2.4. Hereditary Syndromes 
 The familial form of colorectal cancer has become a major public health problem due to its 
relatively high frequency among western population. From the total number of CRC cases, ~80% are 
sporadic (see 3.2.5.), and ~20% are familial or inherited forms147.  
Among the familial cases, i) 10-15% are probably caused by gene mutations and 
polymorfisms of low penetrance, of which the I1307K polymorphism in the APC gene is the best 
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example, ii) ~1% are tumors with chromosomal instability (CIN), with a tendency to appear on the left 
side colon, showing aneuploid DNA, carrying characteristic mutations (in APC, KRAS, and p53), and 
behaving aggressively, being familial adenomatous poliposis (FAP) the most common example, and 
iii) between 5% and 8% are tumors classified as HNPCC based on the Amsterdam and Bethesda 
criteria, (Figure 18).  
 
Among the HNPCCs, accounting for 3-5% of total CRC, there are cases with germline 
mutations in one allele of a MMR gene (predominantly in hMLH1 and hMSH2, but also in hMSH6, and 
hPMS2 genes). These cancers show MSI, arise predominantly on the right side colon, with diploid 
DNA, harboring characteristic mutations (in TGFBR2, and BAX), and behaving less aggressively. The 
remaining HNPCC and HNPCC-like cases are still molecularly unexplained. Several important studies 
have contributed to the increase in our knowledge about these hereditary syndromes and many 
reviews have put together what is known thus far44, 71, 102, 121, 137, 146-161.  
Below, FAP will be briefly described and HNPCC will be more extensively discussed.  
 
In FAP patients, numerous (hundreds, even thousands) adenomas arise, mainly in the 
epithelium of the colon, at an early age. If not removed, the initial benign lesions undergo malignant 
degeneration by the age of 40 to 50 years in most of the patients (~100%). 
 FAP is due to germline mutations in the APC gene. Although the polyps are inherently 
benign, the first step of the two-hit hypothesis162 has already taken place: the inherited APC mutation. 
Often, the remaining wild type (wt) allele is mutated or deleted, accelerating the generation of polyps. 
Further mutations (e.g. in KRAS or p53) to APC-mutated cells are much more likely to lead to cancer 
than they would in non-mutated epithelial cells.  
When FAP results from mutations in the APC gene, it is inherited in an autosomal dominant 
(AD) pattern, which means one copy of the altered gene is sufficient to cause the disorder. In most 
cases, an affected person has one parent with the condition.  
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HNPCC 
Hereditary non-polyposis colorectal cancer syndrome, formerly known as Lynch syndrome, is 
the most common form of inherited predisposition to colon cancer.  
It is characterized by the development of colorectal cancers but also by the apparition of 
endometrium cancer, and, less frequently, stomach, small intestine, urinary tract (kidney, renal pelvis, 
and ureter), ovary, and brain cancers147.  
The early age of onset (between the 
age of 40 and 50) and the high penetrance 
(~80%), due to an autosomal dominant 
transmission trait, are the clinical hallmarks of 
this syndrome. Based on that, Amsterdam 
criteria I160 and II161 (Table 2), and Bethesda 
guidelines163, 164 (Table 3) are the 
international diagnostic criteria for HNPCC. 
The Bethesda guidelines are more sensitive 
but less specific than the Amsterdam criteria 
in identifying HNPCC families with 
pathogenic mutations165, 166.  
Another characteristic of HNPCC cases is 
acceleration in the carcinogenic process. In 
the general population, the adenoma/carcinoma transition takes 8 to 10 years, whereas an adenoma 
may emerge as a carcinoma in only 2 to 3 years in the HNPCC subjects151, 167.  
 
As mentioned before, a substantial portion of the HNPCC cases carry a germline mutation in 
one allele of a MMR gene (hMLH1, hMSH2, hMSH6, or hPMS2 genes) whereas the molecular 
mechanism responsible for the remaining HNPCC and HNPCC-like cancers is still unknown. I will 
focus my attention on the first group.  
Such mutations are detected in ~80% of HNPCC families168-170, primarily affecting hMLH1 
(~50%), hMSH2 (~40%), and hMSH6 (~10%), and less frequently hPMS2171 and hMLH3172 (Table 4).  
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These mutations, called “first hit”, are not enough to cause MSI, but a “second hit”, or somatic 
mutation, which inactivates the wt allele of the gene, turns on the mutator phenotype (the mutator 
phenotype is a hypothesis that postulates that the mutation rate in the early stages of tumor 
development must be significantly greater than that of normal somatic cells) and the subsequent MSI. 
If the mutation is located in an intergenic region of the gene it may have no biological relevance, but if 
it is sited in a coding region causing a frameshift mutation, biological consequences emerge.  
Inactivation of genes involved in signal transduction (TGFBR2)142, and apoptosis (BAX)143 by 
deletions in poly(A) repeats of their codon regions, favors cell transformation rather than cell death, 
therefore cancer progression. Other genes have been reported to be altered in lower frequency 
(IGFR2173, TCF4174, AXIN2145, GARE175, and B2M176).  
Although these lesions have aggressive histological characteristics (such as poor cell 
differentiation), their prognosis is quite favorable due to lower rates of metastatic potential146, 177, 178. 
This fact could be explained by i) the high number of 
cytotoxic T-lymphocytes present in these tumors, 
which, activated by the mutated peptides of the 
cancer cell surface, trigger tumor cell apoptosis, and 
ii) a lower MMR-deficient cell viability due to 
spontaneous mutagenesis, although the molecular 
mechanisms of this event are still unclear. 
The evolution of the two inherited CRC 
syndromes discussed above, shows interesting 
variations. In FAP, thousands of benign tumors form 
after APC mutation. Each of them slowly progresses 
to malignancy, requiring the sequential accumulation 
of mutations in KRAS and p53, etc. Among so many 
adenomas, some of them will progress to cancer. 
When not treated, the median age of cancer 
diagnosis is 42 (the same as in HNPCC), 25 earlier 
than the median age of sporadic colorectal cancer 
patients.  
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In HNPCC, adenomas form at approximately the same rate as in the general population. 
Nevertheless, the adenomatous cells with the MMR defect gain mutations at a rate two of three orders 
of magnitude higher than in normal cells. The accumulation of mutations in tumor suppressors and 
oncogenes leads to a rapid progression to cancer. Therefore, FAP can be considered as a disease of 
tumor initiation and HNPCC one of tumor progression (Figure 19).  
 
3.2.5. Sporadic CRC 
Around 10% of all sporadic colorectal cancers show MSI. Differently from HNPCC tumors, in 
which MMR genes are mainly inactivated by mutations, MSI in sporadic CRC is nearly totally due to 
epigenetic inactivation of hMLH1 expression by promoter hypermethylation179.  
Experimental work with cell lines showed that the hypermethylation affects, and thus 
inactivates, both alleles at the same time180. The fact that this phenomenon is already present in non-
neoplastic colorectal mucosa and colorectal adenomas, suggests that it is an early event in the 
process of cancer growth179, 181, 182.  
As mentioned before, CRC can be defined as MSI-H (high degree of MSI), MSI-L (low degree 
of MSI), and MSS (microsatellite-stable tumors). The group of MSI-H colorectal cancers include 
tumors that; i) arise predominantly on the proximal colon, ii) have diploid DNA content, iii) are poorly 
differentiated, and iv) have better survival183-186. The clinicopathological characteristics do not seem to 
be able to distinguish MSI-L from MSS tumors187-189, but there is not an agreement about whether 
MSI-L tumors should be considered separate from MSS tumors or not.  
On the other hand, it has been shown that methylation inactivates other genes besides 
hMLH1.  
Hence, tumors in sites other than the 
colon can appear through different tumorigenic 
pathways. Despite this fact, the histology and 
biology of such tumors are very similar, thus, they 
are identified as “sporadic tumors of the HNPCC 
spectrum” (Table 5).  
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A considerable portion (2% to 50%137, 146, 178) of other sporadic cancers (breast, prostate, lung, 
bladder, and others), known as “sporadic tumors not belonging to the HNPCC spectrum”, also carry 
MMR defects (Table 6). Among these tumors, and different from HNPCC and sporadic tumors of the 
HNPCC spectrum, MMR defects do not seem to start the malignant process because they arise in late 
stages of tumorigenesis. Nevertheless, MSI status can still be used as a genetic prognostic marker in 
these cancers to choose the optimal therapeutic strategies for each case.  
However, around 90% of the sporadic colorectal cancers do not carry MSI. The sequential 
model for CRC genesis71 (Figure 20) claims that mutations in the APC gene, and less frequently in the 
beta-catenin-encoding gene and AXIN2, are required for tumor initiation. Subsequent progression 
towards malignancy is accompanied by other mutational alterations, affecting oncogenes (KRAS), 
tumor suppressor genes (p53), and other unknown genes, as well as epigenetic events190.  
 
Tumor progression is driven by the selection of specific genetic (and epigenetic) alterations 
that accumulate in strict order. In fact, whereas mutation events are random, the order in which they 
accumulate is non-random, supporting robustly the theory that only certain mutations confer selective 
advantage to a tumor to progress depending on its stage.  
Adenomas are the precancerous lesions from which the malignant tumors arise. The 
malignant potential of an adenoma depends on its size, histologic type, and degree of atypia. 
Adenomatous polyps larger than 1 cm, with a large villous histologic component or with severe 
dysplasia have an increased frequency of malignant change. Only around 10-15% of these polyps 
progress to cancer and such progression generally takes around ten years. In MMR-deficient HNPCC 
patients, this progression period is reduced to approximately two years. Colorectal polyps are usually 
asymptomatic, frequently found during screening for colorectal cancer, and removed via colonoscopy. 
This procedure is adequate for most adenomas, including those with severe grade of dysplasia. The 
polyps which during exploration are found to be malignant may require surgical resection to ensure the 
complete elimination of cancer cells.  
Colon cancer staging is an estimate of the condition of a particular cancer for diagnostic and 
research purposes. The systems for staging colorectal cancers largely depend on the extent of local 
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invasion, the degree of lymph node involvement, and whether there is distant metastasis. The most 
common currently used system for staging is the TNM system (Figure 21A). Since the number of 
combinations of categories is high, combinations are grouped to stages for better analysis (Figure 21B 
and C).  
The aims for adopting a global standard staging system are to i) aid medical staff in staging 
the tumor and thus helping to plan the treatment, ii) give an indication of prognosis, iii) assist in the 
evaluation of the results of treatment, and iv) enable facilities around the world to collect information 
more productively. 
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4. RESULTS (summary of the publications) 
 
“Transcriptome profile of human colorectal adenomas” Jacob Sabates-Bellver*, Laurens G. van 
der Flier*, Mariagrazia de Palo, Elisa Cattaneo, Caroline Maake, Hubert Rehrauer, Endre Laczko, 
Michal A. Kurowski, Janusz M. Bujnicki, Mirco Menigatti, Judith Luz, Teresa V. Ranalli, Alfredo 
Pastorelli, Roberto Faggiani, Marcello Anti, Josef Jiricny, Hans Clevers and Giancarlo Marra. In press, 
Molecular Cancer Research. *These authors contribute equally to this work (Appendix I).  
 
 The objectives of this study were to characterize the global gene expression changes 
occurring during the transition from the normal to the adenomatous epithelium in the colon and to 
identify novel biomarkers of these tumors.  
Using a standardized microarray platform covering the entire human genome, we analyzed 
the transcriptional features of 32 prospectively collected colorectal adenomas, each with matched 
samples of normal mucosa.   
 We first showed that the expression profiles of the adenomas could be easily distinguished 
from that of the normal mucosal samples by using different unsupervised analyses.  
 Gene Ontology analysis revealed that the biological processes more frequently represented 
by genes found up-regulated in adenomas were mitosis, cell division, DNA replication and spindle 
organization, whereas host immune defense, inorganic anion transport, organ development and 
inflammatory response were the most over-represented processes by genes found down-regulated in 
this lesions.  
 Since the Wnt signalling pathway is the physiological regulator of epithelial homeostasis, we 
performed a gene expression analysis of all the genes presently considered involved in this pathway. 
We found out that almost half of them (45%) showed statistically significant expression changes in 
adenomas, whereas 34% remained unchanged and 21% were expressed neither in the normal 
colorectal mucosa nor in the adenomas. 
 Using Canonical Correspondence Analysis (a supervised variant of the Correspondence 
Analysis), we correlated the gene expression profiles with the clinico-pathological characteristics of the 
adenomas. This analysis revealed that the expression profile of adenomas with a diameter >20 
millimetres could be easily distinguished from that of smaller adenomas. This observation is relevant 
because the dimension of the adenomas is considered an prognostic factor. We are in the process of 
identifying the gene expression changes that are more relevant to the growth of adenomas. 
We then focused on KIAA1199, a gene encoding a protein with an unknown function. This 
gene was over-expressed ~55 and ~39 fold in adenomas and carcinomas, respectively. We showed 
that KIAA1199 expression level significantly correlate with that of many well known Wnt target genes. 
Furthermore, its expression was down-regulated after induction of dominant negative TCF4, beta-
catenin siRNA, or N-terminal deleted TCF4 mutant, all of them inhibitors of the Wnt-pathway, 
suggesting its Wnt target status. These evidences confirmed the results obtained in our previous work 
(“The intestinal Wnt/TCF signature”, Appendix II). 
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By in situ hybridization and immunohistochemistry we showed that KIAA1199 mRNA and 
protein were predominantly expressed in the proliferating compartment of normal intestinal crypts, with 
much higher expression levels in dysplastic and neoplastic glands. This expression pattern is 
reminiscent of that of many Wnt target genes. KIAA1199 was expressed in the cytoplasm, particularly 
in the luminal side of the dysplastic cell multilayer.  
Based on our data, we concluded that KIAA1199 is a novel biomarker of colorectal neoplasia 
and displays potential as an interventional target.  
 
 
 
“The intestinal Wnt/TCF signature” Laurens G. Van der Flier*, Jacob Sabates-Bellver*, Irma Oving, 
Andrea Haegebarth, Mariagrazia de Palo, Marcello Anti, Mareielle E. van Gijn, Saskia Suijkerbuijk, 
Marc Van de Wetering, Giancarlo Marra and Hans Clevers. Gastroenterology 2007; 132:628-32. 
*These authors contribute equally to this work (Appendix II).  
 
 The goal of this publication was to describe a core target gene program, the Wnt/TCF 
signature gene set, responsible for the transformation of human intestinal epithelial cells. 
 Comparing the transcriptome of two colorectal cancer cell lines (stably transfected with 
dominant negative TCF4 or TCF1 to block the Wnt signalling pathway) with that of colorectal 
adenomas, adenocarcinomas and normal mucosa (were the Wnt signalling pathway is abnormally 
activated), we found out new target genes of this pathway.  
 We identified new putative Wnt target genes related to the different stages of carcinogenesis; 
adenomas, adenocarcinomas, and both tumor conditions (51, 36 and 121 genes, respectively).   
 By in situ hybridization on Apcmin mice (these mice carry a mutant Apc allele, developing 
multiple adenomas, primarily in the small intestine), and based on the staining patterns observed in 
the crypts, the putative Wnt target genes could be grouped in three different categories. Genes in the 
first category were expressed in the proliferative compartment of the crypts. Approximately half of the 
genes displayed a gradient of decreasing signal along the base of the villus. For the remaining genes 
in this category, mRNA expression was restricted to the proliferative compartment of the crypt proper 
with a steep gradient towards the crypt-villus junction. The second category comprised Paneth cell 
maturation markers. In the third category we found genes whose staining pattern is limited to 1-5 crypt 
cells near the crypt bottom, were the crypt stem cells have been mapped previously.  
 Basically, the Wnt/TCF signature gene set defines the core program activated by TCF4 in 
intestinal epithelial cells . The individual genes within the signature represent promising targets for 
therapy of colorectal cancer, since their expression is consistently activated as the direct result of 
oncogenic Wnt pathway mutations, while many target genes will be causally involved in the 
transformed behavior of the neoplastic cells.  
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“Defective DNA Mismatch Repair Determines a Characteristic Transcriptional Profile in 
Proximal Colon Cancers” Massimiliano di Pietro*, Jacob Sabates Bellver*, Mirco Menigatti, Fridolin 
Bannwart, Annelies Schnider, Anna Russell, Kaspar Truninger, Josef Jiricny and Giancarlo Marra. 
Gastroenterology 2005; 129:1047-1059. *These authors contribute equally to this work (Appendix III).  
 
The aim of this study was to characterize the transcriptional profile of mismatch repair 
deficient (MMR-) colon carcinomas, which represent a sub-group of colon cancers with peculiar 
molecular, pathologic and clinical features (microsatellite instability, conspicous lymphocityc infiltration, 
preferential localization in the proximal colon, and better prognosis).  
In an unsupervised analysis of microarray data, we showed that MMR status (MMR- or 
MMR+) was the most important variable which allowed an almost perfect clustering separation of the 
proximal colon cancers included in our series. We identified a MMR-status signature of 100 genes, 
whose gene expression changes perfectly segregated the MMR+ cancers from the MMR- deficient 
ones and that most likely explain the clinico-pathological differences between these two kinds of colon 
cancers.  
We also identified gene expression alterations, relative to expression in normal colon mucosa, 
specific to mismatch repair deficient (MMR-) or mismatch repair proficient (MMR+) colon cancers. We 
named this group of 39 genes the MMR-related tumorigenesis signature.  
In order to isolate the changes more likely localized in the epithelial-cell component of the 
colon cancers (avoiding a possible dilution effect due to presence of stroma) we compared the gene 
expression profiles of the cancers with those of the colon cancer epithelial cell lines. Genes with 
similar expression changes (MMR+ > MMR- or MMR- >MMR+) in the cancer samples and the colon 
cancer cell lines presumably reflect an epithelial-cell specific alteration. We designated this group of 
54 genes as the MMR-related epithelial-cell signature.  
Since genetic alterations caused by MMR deficiency itself (e.g., microsatellite instability within 
the coding or regulatory regions of genes expressed by cancerous epithelial cells) might lead to some 
of the transcriptional differences seen between MMR- and MMR+ cells, we analyzed the frequency of 
microsatellites in the cDNAs of the genes contained in the MMR-related epithelial-cell signature by 
comparing them to 100 control genes. We found out that microsatellites consisting of ≥8 repeat units in 
the coding region and/or in the 5’UTR and /or ≥12 repeat units in the 3’UTR were significantly more 
common and longer in the MMR-related epithelial-signature genes than those observed in control 
genes. We suspected that MSI in these microsatellites might affect the stability of the transcripts. We 
confirmed microsatellite instability in repeats of the 3’UTR of three genes found differently expressed 
in MMR- cancers: NUTF2, HNRPL and CTNNB1.  
Due to the conspicous lymphocytic infiltration characteristic of MMR- cancers, we focused on 
genes involved in the immune response against tumor cells. By using real-time RT-PCR, we confirmed 
the high mRNA levels of 4-1BBL (TNSFS9), a gene that plays a crucial role in the anti-tumor 
response, in MMR- cancers. Furthermore, the high expression of this gene was associated with a high 
expression of the corresponding protein in MMR-deficient colon cancer cell lines studied by flow 
cytometry. We proposed 4-1BBL as a biomarker of MMR-deficient colon cancers and suggest its 
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potential as a target for therapeutic drugs development supported by the fact that it is not expressed in 
the cells of the colon normal mucosa. 
Finally, we compared the transcriptome of colon cancers (independently of their MMR status) 
with that of the colon normal mucosa to find out genes important for colon carcinogenesis in general. 
We find 182 genes with significantly different expression levels between normal mucosa and colon 
cancers with a fold change ≥4. The involment of many of these genes in colon carcinogenesis has 
been reported in previous studies, but a number of gene expression changes are novel findings. 
It is worth mentioning that microarray data were obtained using the HG-U95v2 arrays from 
Affymetrix, which contain approximately 12000 probes. However, we have recently hybridized the 
same RNA samples with Affymetrix HG-U133plus2.0 arrays, which contain oligonucleotides 
representing the entire human genome. These new results will give us a much wider perspective on 
the gene expression changes in colon cancer (these data will be the subject of a different study). 
 
 
 
“The transcriptome of ileal and colonic normal mucosa” Jacob Sabates-Bellver, Tobias 
Gonzenbach, Endre Laczko, Hubert Rehrauer, Caroline Maake, Fridolin Bannwart, Annelies Schnider, 
Josef Jiricny and Giancarlo Marra. Manuscript in preparation (Appendix IV).  
 
 The aim of this study was to obtain a comprehensive comparative transcriptional analysis of 
human colon and ileum normal mucosa tissues to find out genes and pathways responsible for the 
different incidence of adenocarcinomas (in colon is much higher than in ileum) in these two GI tracts 
considered so far rather similar in morphology and cellular organization. 
 Twelve paired colonic and ileal normal mucosa samples from 12 patients were used for 
microarray data analysis. Different unsupervised analyses of the transcriptional levels of the 
expressed genes effectively segregate the two groups.  
 We performed Gene Ontology analysis with the list of genes whose expression in the two 
parts of the GI tract differed significantly. We found that the genes more expressed in colon were 
primarily implicated in the positive regulation of cell motility and cell migration while those more 
expressed in ileum were principally associated to different aspects of metabolism, protein kinase C 
activation and regulation of apoptosis, among others.  
 Because several signalling pathways maintain the cellular homeostasis in the GI epithelium, 
we looked for changes in the expression levels of genes involved in these pathways, as well as of 
numerous transcription regulators.  
The Wnt signalling pathway is the physiological regulator of epithelial homeostasis and has 
been described that the transformation process to adenoma, and lately to carcinoma, begins in the 
epithelial crypts as a result from qualitative, quantitative and spatial subversion of this pathway. For 
this reason, we also searched for differently expressed genes involved in this pathway.  
 Given that cell renewal rates in ileum and colon are very high and that apoptosis plays a key 
role in this process, we focused our attention on the apoptosis-related genes, particularly in the 
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expression levels of CIDEB and CIDEC, two members of the cell death-inducing DFFA-like effectors 
family. We have found a significant over-expression of these two genes in ileum compared with colon 
normal mucosa. Interestingly, CIDEB and CIDEC mRNA expression levels were further down-
regulated in adenomas and adenocarcinomas of the colon. We are currently analyzing their 
expression at the protein level.  
These preliminary results suggest that CIDEB and CIDEC may play an important role in 
colorectal tumorigenesis prevention. 
 
 
 
“Expression of the MutL Homologue hMLH3 in Human Cells and its Role in DNA Mismatch 
Repair” Elda Cannavo, Giancarlo Marra, Jacob Sabates-Bellver, Mirco Menigatti, Steven M. Lipkin, 
Franziska Fisher, Petr Cejka and Josef Jiricny. Cancer Res 2005; 65 (23): 10759-66 (Appendix V).  
 
In this paper, we showed the participation of hMLH3 in MMR in vitro and its partial redundancy 
with hPMS2, which would be an explanation for the low penetrance of hPMS2 mutations in hereditary 
nonpolyposis colon cancer families (HNPCC families). 
A polyclonal antibody against the COOH terminus of hMLH3, which contains the hMLH1-
interacting domain, was raised to avoid the inconvenient caused by the fact that the commercially 
available hMLH3 antibodies could detect the recombinant protein on WB but failed to detect the 
endogenous protein in all the human cell lines used in this study.  
After having established that the level of hMLH3 in human cells is not dependent on hMLH1 
and that correlates with hMLH3 mRNA, we wondered whether the fluctuation of hMLH3 expression in 
the tested cell lines could be linked to the well known gene silencing process by cytosine methylation. 
The CpG island present in the promoter was found to be methylated giving the mechanism to explain, 
although this is not the only one, the lack of expression of hMLH3. 
Given that hMLH3, hPMS2 and hPMS1 interact with the same region of hMLH1, the 
correlation between the relative abundance of the three different heterodimers and the phenotype of 
the human cells was assessed. We showed that hMLH3 is less abundant than hPMS1 and hPMS2.  
We also showed how, differently from hPMS2 and hPMS1, the presence of hMLH1 is not 
required for the stabilization of hMLH3 in human cells, although it is necessary in baculovirus-infected 
Sf9 cells.  
Finally, we speculated that physiologic levels of hMutLγ might not be sufficient to mediate 
mismatch correction in vivo although in our in vitro MMR assays, the factor could participate in the 
correction of base-base mispairs and one-nucleotide insertion/deletion loops. 
  My direct contribution to this article was concentrated at the RNA level of hMLH3 in cell lines, 
producing the microarray data. We could show a correlation between the RNA and the protein levels 
of hMLH3 in the different cells used in this study. 
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5. Conclusions and perspectives 
 
This section is divided in four different parts, each of them related to one of the projects of my 
thesis (see results and appendixes). 
 
Transcriptome profile of human colorectal adenomas  
Our data represents the first comprehensive transcriptomic analysis of these precancerous 
lesions, and provide evidences of the existence of a broad-scale transcriptome remodeling during 
adenoma formation. 
Expression data subjected to four different unsupervised analyses - Hierarchical clustering, 
Principal component analysis, Correlation analysis, and Correspondence analysis- effectively 
segregated the normal tissues from the adenomas. 
Furthermore, the expression profile of adenomas measuring > 20 mm was easily 
distinguished from those of smaller (= 20 or < 20 mm) adenomas. As expected, larger diameters were 
correlated with high-degree dysplasia. 
We have focused on a series of changes we consider crucial in adenomatous transformation 
in particular those involved in i) regulation of transcription, ii) cell proliferation, cell differentiation and 
apoptosis, iii) cell adhesion, and iv) the Wnt signaling pathway.  
We have identified KIAA1199 as a novel target of the Wnt signaling pathway based on several 
evidences: i) its protein expression at the bottom of the intestinal crypts where the proliferative 
compartment is placed, ii) its up-regulation in adenomas and carcinomas compared to normal mucosa, 
and iii) its down-regulation after blocking the beta-catenin/TCF transcription complex in CRC cell lines.  
Due to the over-expression in colon tumors and to its membrane’s surface localization, we also 
proposed KIAA1199 as a new molecular biomarker of colorectal tumors with capabilities of being a 
potential interventional target.  
Because the function of KIAA1199 is still unknown, our next objectives are to find out i) the 
regulation mechanisms of its expression, ii) the morphological and molecular changes triggered by its 
up- or down-regulation in cell lines, iii) the phenotype of KIAA1199 knock-out animal models, iv) 
whether its up-regulation is specifically linked to colorectal tumors or common to other cancerous 
lesions. 
We will also analyze transcriptional changes between colorectal adenomas and carcinomas in 
order to track expression changes along the entire transformation process from normal mucosa to 
invasive cancer. 
 
The intestinal Wnt signaling pathway 
To identify new Wnt target genes is a subject of great interest to better understand cancer 
progression. On this regard, we have performed a combined transcriptomic analysis using colorectal 
cancer cell lines, normal mucosa, adenoma, and carcinoma colon samples, to identify new targets of 
this pathway. With this approach (see Appendix II), we have found putative Wnt target genes related 
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to the different progression stages of the carcinogenic process. We classified these genes, based on 
their expression localization, in three different groups: i) genes expressed in the proliferative 
compartment of the crypts. Approximately half of the genes displayed a gradient of decreasing signal 
along the base of the villus. For the remaining genes in this group, mRNA expression was restricted to 
the proliferative compartment of the crypt proper with a steep gradient towards the crypt-villus junction, 
ii) Paneth cells maturation markers, and iii) putative stem cells markers, i.e., genes whose staining 
pattern was limited to 1-5 crypt cells near the crypt bottom. 
At this point, as we did for KIAA1199, these putative Wnt target genes should be individually 
validated with other techniques (such as Northern blotting, in situ hybridization, reporter gene 
experiments, ChIP on chip, immunohistochemistry, etc) to prove that their expression is certainly 
regulated by this pathway. 
 
Transcriptional profile of mismatch repair deficient colon cancer 
In order to find out molecular alterations related to the MMR status, we conducted a gene 
expression profile analysis by comparing the transcriptome of MMR-deficient with that of the MMR-
proficient tumors and cell lines.  
We identified a MMR-status signature of 100 genes, whose gene expression changes 
perfectly segregated the group of MMR+ cancers from that of MMR- deficient.  
Gene expression alterations specific to mismatch repair deficient (MMR-) or mismatch repair 
proficient (MMR+) colon cancers, relative to expression in normal colon mucosa, were also identified 
and named as MMR-related tumorigenesis signature. 
A MMR-related epithelial-cell signature containing epithelial-cell specific alterations was as 
well identified. 
Our data showed several changes that might explain the better prognosis associated with 
MMR-deficient colon cancers. Compared with MMR-proficient cancers, MMR-deficient tumors 
presented reduced transcript levels of several genes with functions that presumably favor tumor 
progression and increased expression of factors believed to inhibit tumor growth, progression, and/or 
invasiveness. 
Among the genes found to be more expressed in MMR-deficient tumors, we identified 4-1BBL 
(TNSFS9), a key player in the anti-tumoral response mechanism, as a biomarker of this type of 
cancers. Given that 4-1BBL is not expressed in the colon normal mucosa, its over-expression in MMR-
deficient lesions could be exploited for a novel therapeutic approach in this subgroup of colon cancers.  
We suspected that some of the expression changes might conceivably reflect transcriptional 
effects of MSI within the coding or regulatory regions of genes expressed by cancerous epithelial cells, 
and we confirmed such hypothesis by the finding of a higher frequency of microsatellites in the 
complementary DNAs of the MMR-related epithelial cell signature genes compared with that of 
randomly selected expressed. 
The microarray platform we used screened only ~10000 genes. We have recently repeated 
the analysis using an array that covers the entire human genome. These new data confirmed our 
previous results and brought to light other significant gene expression changes. We are currently 
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analyzing the list of genes obtained to select interesting candidates for further investigation. We are 
also planning to combine these data with the information obtained from a brand new type of array, 
called Exon Array, which reveals alternative splicing of the genes. 
 
The transcriptome of ileal and colonic normal mucosa 
Although morphology and cellular organization in different tracts of the lower GI tract are 
considered quite similar, physiology and cancer incidence are strikingly different.  Thus, we performed 
a transcriptome analysis in ileum and colon normal mucosa tissues in order to identify gene 
expression patterns that might offer new work hypotheses to achieve a better molecular understanding 
of these differences.  
Amongst the genes significantly changed between the two groups, we focused on those 
involved in transcription regulation, cell proliferation/differentiation, Wnt signaling pathway, and 
apoptosis.  
In the apoptosis-related list of genes, we found the cell death-inducing DFFA-like effectors 
CIDEB and CIDEC markedly more expressed in ileum than in colon. In addition, these two genes were 
further down-regulated in adenomas and adenocarcinomas of the colon. We are currently checking 
whether the CIDEB and CIDEC proteins are also differentially expressed in the two epithelia and how 
their expression is distributed along the crypt-villous axis.  Based on these experiments, we will 
evaluate the feasibility of a new project aiming to verify whether the modulation of CIDEB and CIDEC 
expression in mouse ileum and colon might modify the incidence of adenocacinoma in these two 
tissues.  
The analysis of genes involved in signaling pathways controlling the cellular homeostasis in 
the intestinal mucosa, such as Notch, TGF-beta, BMP, Hedgehog, or RAS/RAF, is also in progress. 
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